GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (TSE:4503) » Definitions » EV-to-FCF

Astellas Pharma (TSE:4503) EV-to-FCF : 27.20 (As of Jan. 18, 2025)


View and export this data going back to 1949. Start your Free Trial

What is Astellas Pharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Astellas Pharma's Enterprise Value is 円3,272,291 Mil. Astellas Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was 円120,287 Mil. Therefore, Astellas Pharma's EV-to-FCF for today is 27.20.

The historical rank and industry rank for Astellas Pharma's EV-to-FCF or its related term are showing as below:

TSE:4503' s EV-to-FCF Range Over the Past 10 Years
Min: 8.94   Med: 16.34   Max: 50.48
Current: 27.2

During the past 13 years, the highest EV-to-FCF of Astellas Pharma was 50.48. The lowest was 8.94. And the median was 16.34.

TSE:4503's EV-to-FCF is ranked worse than
55.11% of 548 companies
in the Drug Manufacturers industry
Industry Median: 23.77 vs TSE:4503: 27.20

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-01-18), Astellas Pharma's stock price is 円1494.00. Astellas Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was 円30.420. Therefore, Astellas Pharma's PE Ratio (TTM) for today is 49.11.


Astellas Pharma EV-to-FCF Historical Data

The historical data trend for Astellas Pharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma EV-to-FCF Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.26 12.30 17.43 13.01 38.96

Astellas Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.33 28.78 38.96 34.62 29.48

Competitive Comparison of Astellas Pharma's EV-to-FCF

For the Drug Manufacturers - General subindustry, Astellas Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's EV-to-FCF falls into.



Astellas Pharma EV-to-FCF Calculation

Astellas Pharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3272291.063/120287
=27.20

Astellas Pharma's current Enterprise Value is 円3,272,291 Mil.
Astellas Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円120,287 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (TSE:4503) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Astellas Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1494.00/30.420
=49.11

Astellas Pharma's share price for today is 円1494.00.
Astellas Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円30.420.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Astellas Pharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines